These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30649746)

  • 1. Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation.
    Miner PB
    Drug Saf; 2019 May; 42(5):603-615. PubMed ID: 30649746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
    Miner PB
    Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plecanatide for the treatment of chronic idiopathic constipation in adult patients.
    Bassotti G; Usai Satta P; Bellini M
    Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1019-1026. PubMed ID: 31575291
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
    Shah ED; Kim HM; Schoenfeld P
    Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plecanatide: First Global Approval.
    Al-Salama ZT; Syed YY
    Drugs; 2017 Apr; 77(5):593-598. PubMed ID: 28255961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
    Miner PB
    Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
    [No Abstract]   [Full Text] [Related]  

  • 7. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
    Miner PB; Koltun WD; Wiener GJ; De La Portilla M; Prieto B; Shailubhai K; Layton MB; Barrow L; Magnus L; Griffin PH
    Am J Gastroenterol; 2017 Apr; 112(4):613-621. PubMed ID: 28169285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials.
    Moshiree B; Schoenfeld P; Franklin H; Rezaie A
    Clin Ther; 2022 Jan; 44(1):98-110.e1. PubMed ID: 35086735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial.
    Barish C; Dorn S; Fogel RP; Patel R; Rosenberg J
    Dig Dis Sci; 2021 Feb; 66(2):537-540. PubMed ID: 32185662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.
    Love BL
    Am J Med; 2019 May; 132(5):572-575. PubMed ID: 30550753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.
    Menees SB; Franklin H; Chey WD
    Clin Ther; 2020 Jul; 42(7):1406-1414.e4. PubMed ID: 32660770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plecanatide (Trulance) for chronic idiopathic constipation.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):66-68. PubMed ID: 28419073
    [No Abstract]   [Full Text] [Related]  

  • 13. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.
    Cash BD; Sharma A; Walker A; Laitman AP; Chang L
    Neurogastroenterol Motil; 2023 Sep; 35(9):e14632. PubMed ID: 37332239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation.
    Waldman SA; Tenenbaum R; Foehl HC; Winkle P; Griffin P
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00016. PubMed ID: 31318728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study.
    Barish CF; Griffin P
    Curr Med Res Opin; 2018 Apr; 34(4):751-755. PubMed ID: 29343131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide.
    Martinez de Andino N
    J Am Assoc Nurse Pract; 2018 Jul; 30(7):412-420. PubMed ID: 29979299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy.
    Sharma A; Herekar AA; Bhagatwala J; Rao SS
    Clin Exp Gastroenterol; 2019; 12():31-36. PubMed ID: 30774407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New pharmacological treatment options for chronic constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
    Jarmuż A; Zielińska M; Storr M; Fichna J
    Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.